Management of diabetes in patients with chronic liver diseases



INTRODUCTION
Glycogenesis and lipogenesis during feeding, as well as glycogenolysis and gluconeogenesis during fasting, are essential functions of the liver in maintaining blood glucose homeostasis. The liver is also the primary site of insulin clearance. Diabetes mellitus (DM), a metabolic condition characterized by impaired blood glucose balance and altered insulin sensitivity, is, predictably, related to the onset, progression, and outcome of chronic liver diseases (CLD).

DIABETES AND CHRONIC LIVER DISEASES

Insulin resistance is a well-known pathophysiological driver of nonalcoholic fatty liver disease (NAFLD) T2DM increases the risk of NAFLD by a factor of 2-5 when it is present. Other CLD etiologies are affected by insulin resistance and diabetes. BMI and fasting blood glucose levels have been shown to interfere with fibrosis score in alcoholic liver disease when normal alcohol intake is controlled for.
Because of the likelihood of a two-way interaction, the connection between diabetes and HCV infection is particularly noteworthy. It is thought that the metabolic disturbances associated with diabetes can help HCV to survive. HCV core protein has been shown to promote ubiquitination of insulin receptor substrate (IRS)-1 and -2 in transfected hepatoma cells and a transgenic mouse model.
DIABETES AND END-STAGE LIVER DISEASES
Diabetes expects more chronic illnesses and adverse health outcomes as CLD progresses to end-stage liver disease (ESLD). Diabetics have a higher death rate than non-diabetics, according to surveys. Diabetes is sometimes associated with more severe hepatic encephalopathy in cirrhotic patients, regardless of the severity of the liver disorder.

Hepatocellular carcinoma (HCC) and HCC-specific mortality were nearly doubled in adults with preexisting diabetes. The risk of HCC increases tenfold as it is linked to alcohol consumption and/or viral hepatitis. Hyperinsulinemia is thought to play a key role in the pathophysiological effect of diabetes on HCC development. A diagnosis of HCC has a poor prognosis, regardless of the cause of the underlying CLD.
HEPATOGENIC DIABETES

Hepatogenic diabetes is described by the occurrence of hyperinsulinemia, insulin resistance, and -cell dysfunction after the onset of cirrhosis. This is believed to be due to the damaged liver's decreased insulin clearance and increased portosystemic shunting.
Insulin tolerance can develop as a result of long-term hyperinsulinemia due to a number of negative feedback mechanisms. The hyperglycemic effect of reduced glucose disposal would be amplified by cirrhosis-induced sarcopenia and impaired glucose efficacy. Additional disease-specific insulin resistance pathways can be triggered by certain etiologies of CLD, such as HCV-induced DM. The combination of chronic hyperglycemia and elevated free fatty acid levels in NAFLD results in pancreatic beta-cell dysfunction and glucolipotoxicity death.
DIABETES AND LIVER TRANSPLANTATION

For patients with ESLD, orthotopic liver transplantation (OLT) is still the only curative choice. Pre-transplant diabetes has been attributed to a lower post-transplant survival rate, according to reports. Diabetes is also an independent predictor of postoperative risks such as heart attacks, pneumonia, kidney dysfunction, and acute graft rejection prior to transplantation. New-onset DM after transplantation is associated with male form, tacrolimus use, and HCV infection.
MANAGEMENT OF DIABETES IN PATIENTS WITH LIVER DISEASES

The second challenge in treating diabetes in patients with liver disease is deciding on a care strategy that is both healthy and efficient. Easy dietary changes are well recognized as important in the medical care of diabetes and liver disease. Antihyperglycemic drugs are often required where dietary changes alone fail to improve targeted glycemic control.
Metformin

Metformin is often used as a first-line oral therapy for T2DM due to its beneficial safety profile and cardioprotective effects. Metformin therapy decreases the chance of HCC by 50-70 percent in diabetic patients with CLD with various etiologies, according to large observational studies. Metformin is frequently withheld from patients with liver diseases due to an overestimation of the risk of metformine-associated lactic acidosis (MALA). MALA is a relatively rare condition, with an estimated incidence of 10 in 100,000 patient-years of exposure in patients without serious renal failure.
Pioglitazone

The peroxisome proliferator-activated receptor-gamma agonist thiazolidinedione pioglitazone improves insulin sensitivity. Aminotransferase levels were standardized in a small pilot study of non-diabetic patients with biopsy-proven NASH. According to the researchers, piog litazone could be uniquely appropriate in the care of selected NASH patients with normoglycemia at baseline owing to its low chance of developing hypoglycemia. An advisory panel opinion supports the use of piog Litazone in patients with NAFLD/NASH for the primary or secondary prevention of cardiovascular disease, as well as the prevention of cirrhosis, liver transplantation, or HCC.
α-glucosidase inhibitors

Aarbose is a pluripotent antihyperglycemic agent in patients with CLD. In the patient population, it has been shown to lower fasting glycemia, postprandial glycemia, mean glycemic heterogeneity, and A1c. Saccharolytic, rather than proteolytic, intestinal bacterial flora have been shown to benefit from acarbose therapy. Serum ammonia levels were decreased while cognitive performance was increased in a randomized, placebo-controlled crossover study.
GLP-1 receptor agonists
GLP-1 receptor agonists, such as exenatide and liraglutide, are becoming an increasingly popular class of incretin-based therapy for the treatment of T2DM due to their ability to induce weight loss and reduce the risk of hypoglycemia. Several preliminary open-label studies of diabetic patients found that treatment with liragsutide reduced hepatic steatosis, aminotransferase levels, and liver fibrosis ranking. GLP-1 agonism's effects on other health outcomes linked to liver disease have yet to be thoroughly studied. Advanced cirrhosis patients should be cautious.

DPP-4 inhibitors
DPP-4 is a membrane-bound and circulating glycoprotein that acts as an enzyme on a variety of substrates. GLP-1 inhibitors are thought to act by slowing GLP-1 degradation upstream. Hormonal, immunologic, and neurological symptoms are also possible. Most DPP-4 antagonists, with the exception of vildagliptin, are considered safe in patients with moderate to serious hepatic disability. A recent meta-analysis of five clinical trials observed a slightly increased risk of heart failure hospitalization in diabetic patients with pre-existing cardiovascular risk factors, which was due to the use of D PP-4 inhibitors by those with pre-existing cardiovascular risk factors.
Sodium-glucose cotransporter-2 inhibitors

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors block renal tubular glucose reabsorption rather than immediately altering insulin supply or sensitivity. They have a low chance of hypoglycemia which can help you lose weight while still lowering your blood pressure. They have been shown to enhance hepatic steatosis and liver fibrosis in many animal models of NAFLD/NASH.
Sulfonylureas and meglitinides

Insulin secretagogues are antihyperglycemic drugs that can reduce A1c levels by 1% to 2%. In patients with hepatic more info deficiency, they also pose a high risk of hypoglycemia. In chronic ALD or hemochromatosis, these drugs can become inactive. They should be stopped or used with strict caution in CLD/ESLD patients, according to experts. Sulfonylureas can increase the risk of HCC by up to three times in patients.
Insulin

In diabetic patients, insulin and insulin analogs remain the safest and most effective glycemic treatments. Hypoglycemia, unsurprisingly, is a major limiting side effect. Retrospective studies have shown a connection between insulin therapy and the development of HCC in T2DM patients. To separate the oncogenic risk of insulin therapy from the cardiometabolic risk of uncontrolled hyperglycemia, further research is required. According to the authors, insulin therapy should be reserved for people who are unable to receive or who are not properly treated with other antihyperglycemic medications. The authors prescribe daily dose changes and close glucose monitoring to minimize the chance of hypoglycemia. They come to the conclusion that insulin therapy can only be provided to those who have cirrhosis who are unable to benefit from it.

GLYCEMIC TARGETS IN PATIENTS WITH LIVER DISEASES

Establishing a practical glycemic target is the third challenge in treating diabetes in patients with CLD. For the general non-pregnant adult population, the ADA recommends an A1c target of 7%. It's unclear if the degree of glycemic control is linked to the incidence or incidence of liver disease complications. More research is desperately needed to help determine the best glycemic targets based on the cause of liver disease and the severity of decompensation.

CONCLUSION
Concurrent DM and CLD are associated with worse health outcomes, including shorter life expectancy, more severe liver failure-related risks, and a higher risk of HCC and HCC-specific mortality. FPG, OGTT, and CLD-A1c are examples of alternative glycemic markers that can be used to validate a diabetes diagnosis.
Calorie control and moderate-intensity exercise are examples of lifestyle therapies that can be considered first-line therapy. Unless otherwise contraindicated, metformin can be used as the pillar of antihyperglycemic pharmacotherapy due to its favorable safety profile, chemopreventive impact, and mortality advantage.
The decades-long movement to revise the definition and nomenclature of NAFLD has been re-energized by a recent consensus statement backed by a consortium of international experts. Alcohol consumption or other concomitant liver disorders are no longer needed in the newly suggested definition of metabolic dysfunction-associated fatty liver disease (MAFLD).

Leave a Reply

Your email address will not be published. Required fields are marked *